Andere Sprachen RepliCel Life Sciences Inc.

Aktien

A2APX7

CA76027P4006

REPCF

Markt geschlossen - OTC Markets Andere Börsenplätze 16:20:42 15.03.2024			% 5 Tage	% 1. Jan.
0,0428 ^USD	+4,99 %		+0,08 %	-4,81 %

2023	RepliCel Life Sciences Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI
2023	RepliCel Life Sciences Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Canadian Investment Regulatory Organization Trading Halt - RP	08.05.
RepliCel Life Sciences : Announces Secured Loan Agreement	18.04.
RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18.04.
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K	20.03.
RepliCel Life Sciences : Letter of Intention (Asset Purchase)	18.03.
Canadian Investment Regulatory Organization Trading Halt - RP	15.03.
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	30.11.
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28.11.
RepliCel Life Sciences : Arbitration decision	16.11.
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	24.10.23
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24.10.23
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials	22.09.23
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	30.08.23
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K	17.08.23
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17.08.23
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17.08.23
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K	10.08.23
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	31.05.23
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30.05.23
RepliCel Life Sciences : Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options - Form 6-K	18.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen RepliCel Life Sciences Inc.

Aktien

A2APX7

CA76027P4006

REPCF

Andere Sprachen

Filter